Innate Pharma (IPHA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Innate Pharma (IPHA) has a cash flow conversion efficiency ratio of 1.078x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.40 Million) by net assets ($-21.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Innate Pharma market cap and net worth for the company's overall valuation and market capitalisation.
Innate Pharma - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Innate Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Innate Pharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Innate Pharma ranked by their cash flow conversion efficiency. Explore Innate Pharma (IPHA) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GalaxiaMoneytree Co.Ltd
KQ:094480
|
0.063x |
|
LEWAG Holding Aktiengesellschaft
F:KGR
|
-0.084x |
|
Sat Nusapersada Tbk
JK:PTSN
|
0.031x |
|
ZenaTech Inc.
NASDAQ:ZENA
|
-0.230x |
|
Sungshin Cemen
KO:004980
|
0.018x |
|
MOLECULAR PARTNERS ADS/1
F:6ML0
|
-0.184x |
|
American Well Corp
NYSE:AMWL
|
-0.004x |
|
Samindo Resources Tbk
JK:MYOH
|
0.064x |
Annual Cash Flow Conversion Efficiency for Innate Pharma (2005–2025)
The table below shows the annual cash flow conversion efficiency of Innate Pharma from 2005 to 2025. View IPHA stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-21.69 Million | $-50.67 Million | 2.336x | +399.21% |
| 2024-12-31 | $8.83 Million | $-6.90 Million | -0.781x | -2.85% |
| 2023-12-31 | $42.90 Million | $-32.56 Million | -0.759x | -114.58% |
| 2022-12-31 | $54.15 Million | $-19.15 Million | -0.354x | +34.99% |
| 2021-12-31 | $107.44 Million | $-58.46 Million | -0.544x | -63.81% |
| 2020-12-31 | $155.97 Million | $-51.81 Million | -0.332x | -306.78% |
| 2019-12-31 | $217.42 Million | $34.92 Million | 0.161x | +182.58% |
| 2018-12-31 | $167.24 Million | $-32.53 Million | -0.195x | +65.21% |
| 2017-12-31 | $85.96 Million | $-48.06 Million | -0.559x | -30.74% |
| 2016-12-31 | $86.17 Million | $-36.85 Million | -0.428x | -114.82% |
| 2015-12-31 | $72.07 Million | $207.91 Million | 2.885x | +1287.24% |
| 2014-12-31 | $74.63 Million | $-18.13 Million | -0.243x | +10.74% |
| 2013-12-31 | $40.29 Million | $-10.97 Million | -0.272x | +39.28% |
| 2012-12-31 | $23.36 Million | $-10.47 Million | -0.448x | -191.92% |
| 2011-12-31 | $26.62 Million | $12.99 Million | 0.488x | +221.55% |
| 2010-12-31 | $33.52 Million | $-13.45 Million | -0.401x | -218.54% |
| 2009-12-31 | $47.12 Million | $-5.94 Million | -0.126x | +64.67% |
| 2008-12-31 | $41.34 Million | $-14.74 Million | -0.357x | -90.56% |
| 2007-12-31 | $49.61 Million | $-9.28 Million | -0.187x | -3029.85% |
| 2006-12-31 | $56.37 Million | $360.00K | 0.006x | +101.77% |
| 2005-12-31 | $20.07 Million | $-7.25 Million | -0.361x | -- |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated t… Read more